Ficerafusp Alfa + Pembrolizumab for Head and Neck Cancer

This trial tests a new treatment for individuals with certain types of head and neck cancer. It combines two drugs: ficerafusp alfa (an experimental treatment) and pembrolizumab (an immunotherapy drug), to assess their safety and effectiveness before surgery. The trial seeks participants with newly diagnosed, advanced squamous cell carcinoma in areas like the mouth or throat, whose tumors are PD-L1 positive, indicating the presence of a specific protein. Participants must have a type of cancer that can be surgically removed. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on systemic treatment for an active autoimmune disease or using certain immunosuppressive medications, you may not be eligible to participate.

Research has shown that the combination of ficerafusp alfa and pembrolizumab is generally safe for patients. One study found that this treatment has a good safety record and is well-tolerated. Patients in that study showed promising results in fighting cancer, suggesting the treatment could be effective. Another study confirmed the combination's safety for patients with head and neck cancer, with safety findings aligning with existing knowledge about these drugs.

Researchers are excited about combining Ficerafusp Alfa with Pembrolizumab for head and neck cancer because this duo could offer a novel approach to treatment. Unlike traditional options like chemotherapy and radiation, which target cancer cells broadly, Ficerafusp Alfa is designed to enhance the immune system's ability to recognize and destroy cancer cells by activating specific immune pathways. Paired with Pembrolizumab, which blocks a protein that prevents the immune system from attacking cancer cells, this combination has the potential to boost the body's natural defenses more effectively. This innovative mechanism could lead to more precise targeting of cancer cells, potentially improving outcomes for patients with head and neck cancer.

This trial will evaluate the combination of ficerafusp alfa with pembrolizumab for treating head and neck squamous cell carcinoma (HNSCC). Studies have shown that this combination targets two proteins involved in cancer growth, enhancing the immune system's ability to fight the cancer. In some studies, about 31% of patients responded positively to this treatment. Additionally, researchers found this combination safe and effective for patients with advanced stages of this cancer. These findings suggest potential benefits for individuals with high-risk, PD-L1-positive HNSCC.¹³⁶⁷⁸